- Home
- URGN vs WIW Comparison
URGN vs WIW Comparison
Compare URGN & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- WIW
- Stock Information
- Founded
- URGN 2004
- WIW 2004
- Country
- URGN United States
- WIW United States
- Employees
- URGN N/A
- WIW N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- WIW Finance Companies
- Sector
- URGN Health Care
- WIW Finance
- Exchange
- URGN Nasdaq
- WIW Nasdaq
- Market Cap
- URGN 547.1M
- WIW 523.7M
- IPO Year
- URGN 2017
- WIW N/A
- Fundamental
- Price
- URGN $11.19
- WIW $8.55
- Analyst Decision
- URGN Strong Buy
- WIW
- Analyst Count
- URGN 5
- WIW 0
- Target Price
- URGN $44.50
- WIW N/A
- AVG Volume (30 Days)
- URGN 456.4K
- WIW 229.9K
- Earning Date
- URGN 11-06-2024
- WIW 01-01-0001
- Dividend Yield
- URGN N/A
- WIW 11.14%
- EPS Growth
- URGN N/A
- WIW N/A
- EPS
- URGN N/A
- WIW N/A
- Revenue
- URGN $89,363,000.00
- WIW N/A
- Revenue This Year
- URGN $14.43
- WIW N/A
- Revenue Next Year
- URGN $44.44
- WIW N/A
- P/E Ratio
- URGN N/A
- WIW N/A
- Revenue Growth
- URGN 15.64
- WIW N/A
- 52 Week Low
- URGN $10.60
- WIW $8.01
- 52 Week High
- URGN $20.70
- WIW $9.37
- Technical
- Relative Strength Index (RSI)
- URGN 35.94
- WIW 31.48
- Support Level
- URGN $11.93
- WIW $8.65
- Resistance Level
- URGN $12.78
- WIW $8.82
- Average True Range (ATR)
- URGN 0.71
- WIW 0.08
- MACD
- URGN -0.05
- WIW -0.02
- Stochastic Oscillator
- URGN 1.36
- WIW 11.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.